Use of terazosin in prostatodynia and validation of a symptom score questionnaire

Durwood E. Neal, Timothy D. Moon

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

Objective. The purpose of this trial was to study the use of terazosin in nonbacterial prostatitis/prostatodynia, and to evaluate a new symptom score sheet for this disease. Methods. Twenty-five patients who presented with lower urinary tract symptoms suggestive of prostatitis were evaluated for evidence of bacterial infection by Meares-Stamey criteria and found to be negative. They were then treated with the alpha-blocking drug terazosin in doses from 1 to 10 mg. A symptom score index for prostatitis was developed, tested in these patients, and validated against patients with benign prostatic hyperplasia. Normal control patients, who presented for vasectomy, were studied as well. Results. Nineteen patients (76%) responded to one month's therapy, with 11 (58%) remaining asymptomatic three months later. The symptom score index, as measured by Cronbach's alpha measure of index reliability, was excellent at 0.78 and logistic regression analysis demonstrated each prostatitis question to have independent validity (P < 0.001) but not to the extent of the combined score. Conclusions. Terazosin appears effective in treating patients with nonbacterial prostatitis/prostatodynia. This new symptom score is one way to evaluate and track patients with this disease. A randomized, placebo-controlled clinical trial has been initiated to study this.

Original languageEnglish (US)
Pages (from-to)460-465
Number of pages6
JournalUrology
Volume43
Issue number4
DOIs
StatePublished - Apr 1994

Fingerprint

Terazosin
Prostatitis
Vasectomy
Lower Urinary Tract Symptoms
Prostatic Hyperplasia
Surveys and Questionnaires
Bacterial Infections

ASJC Scopus subject areas

  • Urology

Cite this

Use of terazosin in prostatodynia and validation of a symptom score questionnaire. / Neal, Durwood E.; Moon, Timothy D.

In: Urology, Vol. 43, No. 4, 04.1994, p. 460-465.

Research output: Contribution to journalArticle

@article{8bb858f9b22d46fc9e4e193049c80304,
title = "Use of terazosin in prostatodynia and validation of a symptom score questionnaire",
abstract = "Objective. The purpose of this trial was to study the use of terazosin in nonbacterial prostatitis/prostatodynia, and to evaluate a new symptom score sheet for this disease. Methods. Twenty-five patients who presented with lower urinary tract symptoms suggestive of prostatitis were evaluated for evidence of bacterial infection by Meares-Stamey criteria and found to be negative. They were then treated with the alpha-blocking drug terazosin in doses from 1 to 10 mg. A symptom score index for prostatitis was developed, tested in these patients, and validated against patients with benign prostatic hyperplasia. Normal control patients, who presented for vasectomy, were studied as well. Results. Nineteen patients (76{\%}) responded to one month's therapy, with 11 (58{\%}) remaining asymptomatic three months later. The symptom score index, as measured by Cronbach's alpha measure of index reliability, was excellent at 0.78 and logistic regression analysis demonstrated each prostatitis question to have independent validity (P < 0.001) but not to the extent of the combined score. Conclusions. Terazosin appears effective in treating patients with nonbacterial prostatitis/prostatodynia. This new symptom score is one way to evaluate and track patients with this disease. A randomized, placebo-controlled clinical trial has been initiated to study this.",
author = "Neal, {Durwood E.} and Moon, {Timothy D.}",
year = "1994",
month = "4",
doi = "10.1016/0090-4295(94)90231-3",
language = "English (US)",
volume = "43",
pages = "460--465",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Use of terazosin in prostatodynia and validation of a symptom score questionnaire

AU - Neal, Durwood E.

AU - Moon, Timothy D.

PY - 1994/4

Y1 - 1994/4

N2 - Objective. The purpose of this trial was to study the use of terazosin in nonbacterial prostatitis/prostatodynia, and to evaluate a new symptom score sheet for this disease. Methods. Twenty-five patients who presented with lower urinary tract symptoms suggestive of prostatitis were evaluated for evidence of bacterial infection by Meares-Stamey criteria and found to be negative. They were then treated with the alpha-blocking drug terazosin in doses from 1 to 10 mg. A symptom score index for prostatitis was developed, tested in these patients, and validated against patients with benign prostatic hyperplasia. Normal control patients, who presented for vasectomy, were studied as well. Results. Nineteen patients (76%) responded to one month's therapy, with 11 (58%) remaining asymptomatic three months later. The symptom score index, as measured by Cronbach's alpha measure of index reliability, was excellent at 0.78 and logistic regression analysis demonstrated each prostatitis question to have independent validity (P < 0.001) but not to the extent of the combined score. Conclusions. Terazosin appears effective in treating patients with nonbacterial prostatitis/prostatodynia. This new symptom score is one way to evaluate and track patients with this disease. A randomized, placebo-controlled clinical trial has been initiated to study this.

AB - Objective. The purpose of this trial was to study the use of terazosin in nonbacterial prostatitis/prostatodynia, and to evaluate a new symptom score sheet for this disease. Methods. Twenty-five patients who presented with lower urinary tract symptoms suggestive of prostatitis were evaluated for evidence of bacterial infection by Meares-Stamey criteria and found to be negative. They were then treated with the alpha-blocking drug terazosin in doses from 1 to 10 mg. A symptom score index for prostatitis was developed, tested in these patients, and validated against patients with benign prostatic hyperplasia. Normal control patients, who presented for vasectomy, were studied as well. Results. Nineteen patients (76%) responded to one month's therapy, with 11 (58%) remaining asymptomatic three months later. The symptom score index, as measured by Cronbach's alpha measure of index reliability, was excellent at 0.78 and logistic regression analysis demonstrated each prostatitis question to have independent validity (P < 0.001) but not to the extent of the combined score. Conclusions. Terazosin appears effective in treating patients with nonbacterial prostatitis/prostatodynia. This new symptom score is one way to evaluate and track patients with this disease. A randomized, placebo-controlled clinical trial has been initiated to study this.

UR - http://www.scopus.com/inward/record.url?scp=0028229952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028229952&partnerID=8YFLogxK

U2 - 10.1016/0090-4295(94)90231-3

DO - 10.1016/0090-4295(94)90231-3

M3 - Article

C2 - 7512296

AN - SCOPUS:0028229952

VL - 43

SP - 460

EP - 465

JO - Urology

JF - Urology

SN - 0090-4295

IS - 4

ER -